Historical record - last NADAC effective date: 9/18/2024
Product Information
KAZANO 12.5-500 MG TABLET is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $6.5885 per EA under NDC 64764033560. Its NADAC has been published 278 times since Feb 19, 2014.
FDA first approved this application on Jan 25, 2013.
Strength
12.5; 500 mg/1; mg/1
Manufacturer
Takeda Pharmaceuticals America, Inc.NDC
64764033560
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/18/2024
Active Ingredients
ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA203414FDA Approved
1/25/2013
On Market Since
1/25/2013
Pharmacological Classes
Price Statistics
The NADAC for KAZANO 12.5-500 MG TABLET has been published 278 times since Feb 19, 2014, and over the history we have for it it has risen 44.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.5885 per EA |
|---|---|
| All-time high | $6.5908 (Aug 14, 2024) |
| All-time low | $4.5723 (Feb 19, 2014) |
| Median price | $5.8139 |
| Average price | $5.7322 |
| Largest weekly change | +9.9% (Apr 17, 2024) |
| Weeks tracked | 278 |
| Tracking since | Feb 19, 2014 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
+10.0%
5Y
+10.0%
All
+44.1%
Last surveyed Sep 10, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 65% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Takeda Pharmaceuticals America, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
alogliptin and metformin hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of KAZANO 12.5-500 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for KAZANO 12.5-500 MG TABLET, manufactured by Takeda Pharmaceuticals America, Inc., is $6.5885 per EA (NDC 64764033560), effective Sep 10, 2025.
How has the price of KAZANO 12.5-500 MG TABLET changed over time?
Over the history we have for it, the NADAC for KAZANO 12.5-500 MG TABLET has risen 44.1%. It has been tracked across 278 weekly CMS publications since Feb 19, 2014.
What are the highest and lowest recorded NADAC prices for KAZANO 12.5-500 MG TABLET?
Since Feb 19, 2014, the NADAC for KAZANO 12.5-500 MG TABLET has ranged from a low of $4.5723 (Feb 19, 2014) to a high of $6.5908 (Aug 14, 2024), with a median of $5.8139 per EA.
Are there cheaper alternatives to KAZANO 12.5-500 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ALOGLIPTIN-METFORMIN 12.5-500, is $2.3206 per EA — about 65% below KAZANO 12.5-500 MG TABLET.
Who manufactures KAZANO 12.5-500 MG TABLET?
KAZANO 12.5-500 MG TABLET (NDC 64764033560) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.